Table 1 Current major target antigens and clinical trials of TCR-T cell therapy

TDA

MART-1

HLA-A*0201

Melanoma

n.s

n.s

2/17

(12)

2 PR

[34]

MART-1

HLA-A*02:01

Melanoma

NCT00509288

2

6/20

(30)

6PR

[35]

MART-1

HLA-A*02:01

Melanoma

NCT00910650

2

0/13

(0)

0

[36]

MART-1

HLA-A*02:01

Melanoma

NCT02654821

1/2a

2/12

(16.7)

2PR

[37]

gp100

HLA-A*02:01

Melanoma

NCT00509496

2

3/16

(16)

1CR,

2PR

[35]

CEA

HLA-A*02:01

Colorectal cancer

NCT00923806

1

1/3

(33)

1PR

[90]

CGA

NY-ESO-1

HLA-A*02:01

Melanoma; synovial sarcoma

NCT00670748

1

5/11

(45)

4/6

(67)

2CR,

3PR;

4PR

[40]

NY-ESO-1

HLA-A*02:01

Melanoma; synovial sarcoma

NCT00670748

2

11/20

(55);

11/18

(61)

4CR, 7PR; 1CR, 10PR

[41]

NY-ESO-1

HLA-A*02:01

Melanoma; synovial sarcoma; liposarcoma; osteosarcoma; MPNST

NCT02070406; NCT01697527

1

2/10

(20)

2PR

[42]

NY-ESO-1

HLA-A*02:01;HLA-A*02:06

Synovial sarcoma

NCT01343043

1/2

6/12

(50)

1CR, 5PR

[43]

NY-ESO-1

HLA-A*02:01;HLA-A*02:06

Synovial sarcoma

NCT01343043

1/2

9/30

(30)

9PR

[44]

NY-ESO-1

HLA-A*02:01;HLA-A*02:06

Synovial sarcoma

JMA-IIA00346

1

1/3

(33)

1CR

[45]

NY-ESO-1 (CRISPR/Cas9)

HLA-A*02:01

Metastatic sarcoma; Myeloma

NCT03399448

1

0/3

0

[46]

NY-ESO-1

HLA-A*02:01

Myeloma

NCT01352286

1/2

11/25

(44)

1SCR,1CR, 8VGPR, 1PR

[47]

MAGE-A3

HLA-A*02:01

Melanoma; synovial sarcoma; esophageal cancer

NCT01273181

1/2

5/9

(56)

1CR,4PR

[52]

MAGE-A3

HLA-A*01

Melanoma

NCT01350401

1

0/1

0

[51]

MAGE-A3

HLA-DPB1*0401

Metastatic solid tumors

NCT02111850

1

4/17

(23.5)

1CR,3PR

[53]

MAGE-A4

HLA-A*24:02

Esophageal cancer

UMNI000002395

1

0

/

[49]

MAGE-A4

HLA-A*02

Relapsed/refractory metastatic solid tumors (9 types)

NCT03132922

1

9/38

(24)

9PR

[50]

MAGE-10

HLA-A*02:01 OR HLA-A*02:06

Nsclc

NCT02592577

1

1/11

(9)

1PR

[48]

PRAME

HLA-A*02:01

Cutaneous melanoma, uveal melanoma, endometrial carcinoma, synovial sarcoma, and ovarian cancer

NCT03686124

1

8/12

(64)

8PR

[61]

Viral antigen

HPV16-E6

HLA-A*02:01

Epithelial cancer

NCT02280811

1/2

2/12

(17)

2PR

[94]

HPV16-E7

HLA-A*02:01

Epithelial cancer

NCT02858310

1

6/12

(50)

6PR

[95]

HBV

HLA-A*02:01;HLA-Cw0801

HBV-

NCT03899415

1

1/8

(12.5)

1PR

[96]

MCPyV

HLA-A*02:01

Merkel cell carcinoma

NCT03412877

1

1/5

(20)

n.s

[97]

Neoantigen

TP53

HLA-A*02:01

Metastatic breast cancer

NCT03412877

1

1/1

(100)

1PR

[21]

KRAS G12D

HLA-A*08:02

Metastatic pancreatic cancer

IND 27501

1

1/1

(100)

1PR

[22]

mutation-associated neoantigens (CRISPR/Cas9)

multiple HLA class I

Metastatic solid tumors

NCT03970382

1

0/16

0

[23]